IMMATICS

Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting immunotherapies for the treatment of cancer. Immatics is sponsoring several clinical trials to deliver the power of T cells to cancer patients. The purpose of these trials is to develop innovative immunotherapies aimed at targeting a patient's tumor selectively and effectively... Immatics has identified and characterized a trove of novel intracellular tumor targets for the development of cancer immunotherapies. We use this knowledge together with our XPRESIDENT® technology to define true targets, distinct molecular barcodes that identify the tumor cell. This gives us a drug discovery advantage that we aim to leverage for our own proprietary pipeline and for our collaborations with world-leading partners... Immatics' approach towards the goal of opening new avenues of treatment for cancer patients starts with the discovery and validation of true targets (using the..

Also known as: Immatics Biotechnologies, Immatics Biotechnologies GmbH, Immatics N.V., Immatics US, Inc.

Registration numbers: HRB 382151 (W)

VAT numbers: DE813106208

Primary location: Munich Germany